Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

Lei-lei Fu; Mao Tian; Xiang Li; Jing-jing Li; Jian Huang; Liang Ouyang; Yonghui Zhang; Bo Liu

doi:10.18632/oncotarget.3551

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

Lei-lei Fu, Mao Tian, Xiang Li, Jing-jing Li, Jian Huang, Liang Ouyang, Yonghui Zhang and Bo Liu _

PDF | HTML | How to cite

Oncotarget. 2015; 6:5501-5516. https://doi.org/10.18632/oncotarget.3551

Metrics: PDF 6344 views | HTML 8095 views | ?

Abstract

Lei-lei Fu1,*, Mao Tian1,*, Xiang Li1,*, Jing-jing Li1, Jian Huang2, Liang Ouyang1, Yonghui Zhang1,3 and Bo Liu1

1 State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, Department of Urology, West China Hospital, Sichuan University, Chengdu, China

2 School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China

3 Collaborative Innovation Center for Biotherapy, Department of Pharmacology & Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing, China

* These authors contributed equally to this work

Correspondence to:

Bo Liu, email:

Jian Huang, email:

Keywords: bromodomain, BRD2/4, BRD3, BRDT, BET inhibitor

Received: January 22, 2015 Accepted: February 13, 2015 Published: March 12, 2015

Abstract

As a conserved protein interaction module that recognizes and binds to acetylated lysine, bromodomain (BRD) contains a deep, largely hydrophobic acetyl lysine binding site. Proteins that share the feature of containing two BRDs and an extra-terminal domain belong to BET family, including BRD2, BRD3, BRD4 and BRDT. BET family proteins perform transcription regulatory function under normal conditions, while in cancer, they regulate transcription of several oncogenes, such as c-Myc and Bcl-2. Thus, targeting BET proteins may be a promising strategy, and intense interest of BET proteins has fueled the development of structure-based bromodomain inhibitors in cancer. In this review, we focus on summarizing several small-molecule BET inhibitors and their relevant anti-tumor mechanisms, which would provide a clue for exploiting new targeted BET inhibitors in the future cancer therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3551

Publication Alerts

Reviews:

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

Abstract